Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keisuke Shirai

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Immunity|September 15, 2021
Resident memory CD8<sup>+</sup> T cells in regional lymph nodes mediate immunity to metastatic melanomaAleksey K Molodtsov, Nikhil Khatwani, Jennifer L Vella, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 TrialJames Chih-Hsin Yang, D Ross Camidge, Cheng-Ta Yang, et al.
Cancer Immunology, Immunotherapy : CII|December 22, 2017
Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cellsTamson Moore, Courtney Regan Wagner, Gina M Scurti, et al.
JAMA|May 22, 2014
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugsMark G Kris, Bruce E Johnson, Lynne D Berry, et al.
Cancer Immunology, Immunotherapy : CII|October 21, 2017
Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cellsTamson Moore, Courtney Regan Wagner, Gina M Scurti, et al.
Oncoimmunology|September 14, 2020
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patientsTian Zhang, Sarabjot Pabla, Felicia L Lenzo, et al.
Journal for Immunotherapy of Cancer|May 11, 2018
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burdenCarl Morrison, Sarabjot Pabla, Jeffrey M Conroy, et al.
Journal for Immunotherapy of Cancer|January 26, 2019
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitorsJeffrey M Conroy, Sarabjot Pabla, Mary K Nesline, et al.
Journal for Immunotherapy of Cancer|February 3, 2019
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patientsSarabjot Pabla, Jeffrey M Conroy, Mary K Nesline, et al.
The British Journal of Dermatology|October 22, 2024
Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanomaErin McGillivray, Karam Ashouri, Eftychia Chatziioannou, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Immunity|September 15, 2021
Resident memory CD8<sup>+</sup> T cells in regional lymph nodes mediate immunity to metastatic melanomaAleksey K Molodtsov, Nikhil Khatwani, Jennifer L Vella, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 TrialJames Chih-Hsin Yang, D Ross Camidge, Cheng-Ta Yang, et al.
Cancer Immunology, Immunotherapy : CII|December 22, 2017
Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cellsTamson Moore, Courtney Regan Wagner, Gina M Scurti, et al.
JAMA|May 22, 2014
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugsMark G Kris, Bruce E Johnson, Lynne D Berry, et al.
Cancer Immunology, Immunotherapy : CII|October 21, 2017
Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cellsTamson Moore, Courtney Regan Wagner, Gina M Scurti, et al.
Oncoimmunology|September 14, 2020
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patientsTian Zhang, Sarabjot Pabla, Felicia L Lenzo, et al.
Journal for Immunotherapy of Cancer|May 11, 2018
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burdenCarl Morrison, Sarabjot Pabla, Jeffrey M Conroy, et al.
Journal for Immunotherapy of Cancer|January 26, 2019
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitorsJeffrey M Conroy, Sarabjot Pabla, Mary K Nesline, et al.
Journal for Immunotherapy of Cancer|February 3, 2019
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patientsSarabjot Pabla, Jeffrey M Conroy, Mary K Nesline, et al.
The British Journal of Dermatology|October 22, 2024
Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanomaErin McGillivray, Karam Ashouri, Eftychia Chatziioannou, et al.
Pageof 9